Status:
ACTIVE_NOT_RECRUITING
MRI Guided SBRT for Localized Prostate Cancer
Lead Sponsor:
Rush University Medical Center
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
This study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify patients for two different radiotherapy regimens based on the presence/absence of identifiable intraprostat...
Detailed Description
Radiotherapy (RT) is considered standard of care treatment for prostate cancer. Conventional RT regimens consist of 8-9 weeks of daily RT. Recent data support the use of hypofractionated RT (5-6 weeks...
Eligibility Criteria
Inclusion
- Biopsy proven prostate adenocarcinoma within 1 year of randomization
- NCCN Low to High Risk localized prostate cancer
- Zubrod Performance Status 0-1 within 60 days prior to registration
Exclusion
- Prior or concurrent invasive malignancy (except non-melanoma skin cancer)
- Regional Lymph Node (N1) involvement
- Distant Metastases (M1) involvement
- History of prior pelvic irradiation (external beam radiotherapy or brachytherapy)
- Prior chemotherapy
- Severe, active co-morbidities (unstable angina and/or CHF; MI; COPD; liver disease; AIDS)
- Acute bacterial or fungal infection requiring IV antibiotics
- Inability to undergo MRI
- Inability to receive fiducial markers
Key Trial Info
Start Date :
May 23 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2029
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT03778112
Start Date
May 23 2016
End Date
March 1 2029
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Center
Chicago, Illinois, United States, 60612